Developing predictive assays: the phenotypic screening "rule of 3"

Fabien Vincent; Paula Loria; Marko Pregel; Robert Stanton; Linda Kitching; Karl Nocka; Regis Doyonnas; Claire Steppan; Adam Gilbert; Thomas Schroeter; Marie-Claire Peakman

doi:10.1126/scitranslmed.aab1201

Developing predictive assays: the phenotypic screening "rule of 3"

Sci Transl Med. 2015 Jun 24;7(293):293ps15. doi: 10.1126/scitranslmed.aab1201.

Authors

Affiliations

¹ Hit Discovery and Lead Profiling, Pfizer, Groton, CT 06340, USA. [email protected].
² Hit Discovery and Lead Profiling, Pfizer, Groton, CT 06340, USA.
³ Rare Diseases Research Unit, Pfizer, Cambridge, MA 02139, USA.
⁴ Worldwide Medicinal Chemistry, Pfizer, Groton, CT 06340, USA.
⁵ Neusentis Research Unit, Pfizer, Cambridge CB21 6GS, UK.
⁶ Immunology and Inflammation Research Unit, Pfizer, Cambridge, MA 02139, USA.

PMID: 26109101
DOI: 10.1126/scitranslmed.aab1201

Abstract

Phenotypic drug discovery approaches can positively affect the translation of preclinical findings to patients. However, not all phenotypic assays are created equal. A critical question then follows: What are the characteristics of the optimal assays? We analyze this question and propose three specific criteria related to the disease relevance of the assay-system, stimulus, and end point-to help design the most predictive phenotypic assays.

Publication types

Review

MeSH terms

Biological Assay / methods*
Drug Evaluation, Preclinical / methods*
Endpoint Determination
Humans
Phenotype